Search

EHA remembers Tessa Holyoake

The Hague, September 2017

We received the sad news of Professor Tessa Holyoake’s passing. Tessa Holyoake was a Professor of Experimental Hematology and the Head of the Paul O'Gorman Leukemia Research Centre.

Read more

Genome sequencing of thousands of patients with rare blood disorders

Approximately 3M people have a rare bleeding disorder or disease of platelets, which are the cell fragments that help blood clot. The genetic causes of dozens of such disorders are known (e. g.

Read more

Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study

Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.

Read more

Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial

Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.

Read more

Policy on double awarding

We want to support as many young investigators and clinicians as possible in their career development. For this reason, we do not allow ‘double awarding.

Read more

Policy on double awarding

We want to support as many young investigators and clinicians as possible in their career development. For this reason, we do not allow ‘double awarding.

Read more

Policy on double awarding

We want to support as many young investigators and clinicians as possible in their career development. For this reason, we do not allow ‘double awarding.

Read more

Policy on double awarding

We want to support as many young investigators and clinicians as possible in their career development. For this reason, we do not allow ‘double awarding.

Read more